Here you can find detailed press kits on the several disease areas with background information and downloads

In Focus: Personalised Healthcare

Doctor, Patient

Different people respond differently to medicines. The aim of Roche Personalised Healthcare (PHC) is to target treatments to the patients most likely to benefit. This means tailoring treatments to specific patient sub-groups who share similar characteristics in their genetic makeup or in the molecular nature of their disease. This approach has enormous potential to make healthcare better, safer and more effective, with benefits for patients, physicians, payers, and society at large.

Herceptin treatment in breast cancer is a case in point: Measuring the levels of the protein HER2 in breast cancer cells with specific tests such as the assays from Roche Tissue Diagnostics (Ventana) reliably identifies patients who are likely to respond to Herceptin, a medicine that specifically targets HER2. Roche is also applying this approach to the diagnosis and the treatment of HER2-positive metastatic gastric cancer with Herceptin.